IP Library › Granted Patent US 12,453,758
Granted Patent B2
US 12,453,758 · App. 19/098,553 · Granted Oct 28, 2025

Method of using a GIP/GLP1 co-agonist for diabetes

Inventors: Jorge Alsina-Fernandez (Indianapolis, IN); Over Cabrera (Carmel, IN); Tamer Coskun (Carmel, IN)
Assignee: ELI LILLY AND COMPANY
A61K38/26A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,453,758
App. No.
19/098,553
Granted
Oct 28, 2025
Kind
B2
Abstract

The present invention provides methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Furthermore, the present invention provides methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 5:1 GIP to GLP-1. Also, the present invention provides methods of inducing T2D remission using a novel dosing regimen of a GIP:GLP-1 Peptide. The present invention also provides methods of treating obesity using a novel dosing regimen of a GIP:GLP-1 Peptide.

Claims (18)

1. A method of improving weight management in a patient in need thereof, comprising:

a) administering to said patient a first dose of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is greater than or equal to the GIP:GLP-1 receptor agonist potency ratio of a GIP:GLP-1 Peptide having SEQ ID NO: 56 and less than the GIP:GLP-1 receptor agonist potency ratio of a GIP:GLP-1 Peptide having SEQ ID NO: 49, wherein the GIP:GLP-1 agonist potency ratio is measured after a 60 minute incubation using a casein cAMP assay normalized against GIP and GLP-1; and thereafter

b) administering to said patient a second dose of the GIP:GLP-1 Peptide for a minimum of about two weeks; and thereafter

c) administering to said patient a third dose of the GIP:GLP-1 Peptide for a minimum of about two weeks; and thereafter

d) administering to said patient a fourth dose of the GIP:GLP-1 Peptide;

wherein the first dose is about 25% of the fourth dose, the second dose is about 50% of the fourth dose and the third dose is about 75% of the fourth dose.

2. The method of claim 1 , wherein the doses are each administered for about four weeks before the administration of the next higher dose begins.

3. The method of claim 1 , wherein the GIP:GLP-1 Peptide has a receptor agonist potency ratio that is 2.5:1 to about 5:1 GIP to GLP-1.

4. The method of claim 1 , wherein the GIP:GLP-1 Peptide has a receptor agonist potency ratio that is 2.5:1 to about 3.5:1 GIP to GLP-1.

5. A method of treating obesity in a patient in need thereof, comprising:

a) administering to said patient a first dose of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is greater than or equal to the GIP:GLP-1 receptor agonist potency ratio of a GIP:GLP-1 Peptide having SEQ ID NO: 56 and less than the GIP:GLP-1 receptor agonist potency ratio of a GIP:GLP-1 Peptide having SEQ ID NO: 49, wherein the GIP:GLP-1 agonist potency ratio is measured after a 60 minute incubation using a casein cAMP assay normalized against GIP and GLP-1; and thereafter

b) administering to said patient a second dose of the GIP:GLP-1 Peptide for a minimum of about two weeks; and thereafter

c) administering to said patient a third dose of the GIP:GLP-1 Peptide for a minimum of about two weeks; and thereafter

d) administering to said patient a fourth dose of the GIP:GLP-1 Peptide;

wherein the first dose is about 25% of the fourth dose, the second dose is about 50% of the fourth dose and the third dose is about 75% of the fourth dose.

6. The method of claim 5 , wherein the doses are each administered for about four weeks before the administration of the next higher dose begins.

7. The method of claim 5 , wherein the GIP:GLP-1 Peptide has a receptor agonist potency ratio that is 2.5:1 to about 5:1 GIP to GLP-1.

8. The method of claim 5 , wherein the GIP:GLP-1 Peptide has a receptor agonist potency ratio that is 2.5:1 to about 3.5:1 GIP to GLP-1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2026
From: BENSON, CHARLES T.; HAUPT, AXEL; THOMAS, MELISSA KAY; URVA, SHWETA
To: ELI LILLY AND COMPANY
Reel/Frame 074055/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2025
From: ALSINA-FERNANDEZ, JORGE; CABRERA, OVER; COSKUN, TAMER
To: ELI LILLY AND COMPANY
Reel/Frame 071451/0709 →
Continuity (5)
Division 17260279
Provisional Application 62740640 · Oct 3, 2018
Provisional Application 62730562 · Sep 13, 2018
Provisional Application 62702180 · Jul 23, 2018
Related Publication 20250241995A1 · Jul 31, 2025
References Cited (51)
US 9474780B2 · Bokvist et al. · 2016 [cited by applicant]
US 10278923B2 · Nielsen et al. · 2019 [cited by applicant]
US 11357820B2 · Corvari et al. · 2022 [cited by applicant]
US 20130065828A1 · Ruus et al. · 2013 [cited by applicant]
WO 2013164483 · 2013 [cited by applicant]
WO 2014177683A1 · 2014 [cited by applicant]
WO 2015022420A1 · 2015 [cited by applicant]
WO 2015067715A2 · 2015 [cited by applicant]
WO 2016111971A1 · 2016 [cited by applicant]
WO 2017074715A1 · 2017 [cited by applicant]
WO 2020023386A1 · 2020 [cited by applicant]
Chaplin et al. Properties of GLP-1 agonists and their use in type 2 diabetes. Prescriber, (2016), 27(1), 43-46. [cited by applicant]
Ciardullo et al., “GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes,” Acta Diabetologica, https://doi.org/10.1007/s00592-024-02300-6, Published online: Jun. 3, 2024, 10 pages. [cited by applicant]
Closer Look, American Diabetes Association 82nd Scientific Sessions, Jun. 3-7, 2022; New Orleans, LA (+Virtual); Day #2 Highlights—Draft, www.closeconcerns.com, 31 pages. [cited by applicant]
Closer Look, American Diabetes Association 82nd Scientific Sessions, Jun. 3-7, 2022; New Orleans, LA (+Virtual); Day #5 Highlights—Draft, www.closeconcerns.com, 37 pages. [cited by applicant]
Closer Look, ATTD (Advanced Technologies and Treatments for Diabetes) 2022, Apr. 27-30, 2022; Barcelona, Spain (+Virtual); Full Report—Draft, www.closeconcerns.com, 304 pages. [cited by applicant]
Closer Look, Practical Ways to Achieve Targets in Diabetes Care (Keystone) 2024, Jul. 10-13, 2024; Keystone, CO; Day #2 Highlights—Draft, www.closeconcerns.com, 18 pages. [cited by applicant]
Closer Look, www.closerconcerns.com, EASD 2018 (European Association for the Study of Diabetes), Oct. 1-5, 2018; Berlin, Germany; Day #4 Highlights—Draft, pp. 1-29. [cited by applicant]
Coskun et al., LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular metabolism, (2018), 18, 3-14. [cited by applicant]
Del Prato et al., “Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial,” The Lancet, vol. 398, pp. 1… [cited by applicant]
Diabetes_Core_Update_Nov. 2023, diabetesjournals.org, 12 pages (transcript from audio podcast at diabetesjournals.org/journals/pages/diabetes-core-update-podcasts). [cited by applicant]
Fanshier et al., “Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin,” Diabetes Journal, vol. 41, No. 3,… [cited by applicant]
Frias et al., (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The… [cited by applicant]
I8F-MC-GPGH(c) Clinical Protocol, “Protocol I8F-MC-GPGH(c) A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes … [cited by applicant]
I8F-MC-GPGI(b) Clinical Protocol, “Protocol I8F-MC-GPGI(b) A Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide versus Placebo in Patients with Type 2 Diabetes Inadequately Contr… [cited by applicant]
I8F-MC-GPGK(b) Clinical Protocol, “Protocol I8F-MC-GPGK(b) A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Does versus Placebo in Patients with Type 2 Diabetes… [cited by applicant]
I8F-MC-GPGL(b) Clinical Protocol, “Protocol I8F-MC-GPGL(b) A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients w… [cited by applicant]
I8F-MC-GPGM(b) Clinical Protocol, “Protocol I8F-MC-GPGM(b) Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4),” Eli Lilly … [cited by applicant]
Kaneko, “Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes,” Touch Medical Media, DOI: https://doi.org/10.17925/EE.2022.18.1.10, Jun. 16, 2022, pp. 10-19. [cited by applicant]
Ludvik et al., “Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, … [cited by applicant]
MacIsaac et al., Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin, Diabetes Ther (2023) 14:1997-2014, https://doi.org/10.1007/s13300-023-01475-5. [cited by applicant]
Mudalier, Diabetes remission—The holy grail in diabetes management, Chronicle of Diabetes Research and Practice, Jan.-Jun. 2024, vol. 3, Issue 1, pp. 1-4. [cited by applicant]
Nathan et al., (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the Europ… [cited by applicant]
Petri et al., Diabetes Obes Metab. 2018;20:2238-2245 (Year: 2018). [cited by applicant]
Popovic et al., “Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?,” Journal of Diabetes and Its Complications 38 (2024) 108800, 3 pages. [cited by applicant]
Portron et al. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG 7697 after single subcutaneous administration … [cited by applicant]
Pratley et al., Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomized, double blind, phase 3a trial; The Lancet, (online Jun. 8, 2019). [cited by applicant]
Rosenstock et al., “Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials,” Diabetes Care, vol. 46, Nov. 2023, pp. 1986-1992. [cited by applicant]
Rosenstock et al., “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial,” The Lancet, vol. 398, pp. 143-… [cited by applicant]
Schmitt et al. (2017). Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG 7697 in people with type… [cited by applicant]
Sun et al., Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes technology & therapeutics, (2015), 17(1)… [cited by applicant]
Tan et al., “Tirzepatide and the new era of twincretins for diabetes,” The Lancet, vol. 398, pp. 95-97, Jul. 10, 2021, Published Online Jun. 26, 2021, https://doi.org/10.1016/S0140-6736(21)01390-8. [cited by applicant]
Taub, Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine & growth factor reviews, (1996), 7(4), 355-376. [cited by applicant]
Trial NCT02759107, A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM), May 3, 2016 (Year: 2016). [cited by applicant]
Will et al., Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity. Current opinion in pharmacology, (2017), 37, 10-15; 6 pages. [cited by applicant]
Wong et al., (2018). Noninvasive biomarkers in NAFLD and NASH—current progress and future promise. Nature Reviews Gastroenterology & Hepatology, 15(8), 461 https://www.ncbi.nlm.nih.gov/pubmed/29844588. [cited by applicant]
Written Opinion of the International Searching Authority pertaining to International Application No. PCT/US2019/042824; Date of Mailing: Oct. 14, 2019; 10 pages. [cited by applicant]
International Search Report of the International Searching Authority pertaining to International Application No. PCT/US2019/042824; Date of Mailing: Oct. 14, 2019; 6 pages. [cited by applicant]
Younossi et al., Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, (2016), 64(1), 73-84. [cited by applicant]
International Search Report and Written Opinion, PCT Application No. PCT/US2019/042824, mailed date Oct. 14, 2019, pp. 10. [cited by applicant]
European Extended Search Report, EP Application No. 24194825.6, mailed date Nov. 28, 2024, pp. 11. [cited by applicant]